Answers are grounded in this paper and cite their sources.
Cancer's molecular wiring is notoriously hard to untangle, so computational tools have become essential for mapping disease mechanisms and narrowing down therapeutic leads. Here, we applied in silico screening to evaluate the anticancer potential of metabolites from two probiotic gut isolates: Streptococcus equinus WC1 (SE-WC1) and Limosilactobacillus reuteri GM4 (LR-GM4). Lactic acid bacteria are core members of the human gut microbiota, and their metabolic repertoire—ranging from pathogen suppression to immune modulation and vitamin synthesis—has attracted growing scientific attention. GC–MS profiling of volatile hydrocarbons identified lupeol (14.49%) and 1-heptatriacontanol (5.48%) as the major bioactive constituents, with lupeol detectable in both strains at differing abundances. Docking simulations against ten cancer-linked proteins revealed that lupeol bound more strongly than 1-heptatriacontanol at eight out of ten targets. Its calculated free energies ran from − 6.2 kcal/mol (NR1I3) down to − 11.0 kcal/mol (HSD11B1), whereas 1-heptatriacontanol managed only − 3.2 kcal/mol (SHH) to − 6.8 kcal/mol (UGT2B7). The energy gap (ΔΔG) was smallest at GPBAR1 (− 0.4 kcal/mol) and largest at HSD11B1 (− 4.7 kcal/mol), with intermediate differences at AR (− 4.0), SHH (− 3.9), CDC25B (− 3.4), and TRPM8 (− 3.0 kcal/mol). Because lupeol successfully engaged structurally unrelated proteins—nuclear receptors, phosphatases, ion channels, and metabolic enzymes alike—its superior binding appears to stem from inherent scaffold properties rather than target-specific recognition.
No takes yet. Share an insight, caveat, or question.
Ashour et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: